At SAWC Fall 2025, Dr. Daniel L. Kapp, board-certified plastic surgeon and nationally recognized authority in wound reconstruction and biologic therapies, led an insightful session on the growing clinical burden of non-healing post-surgical wounds and the emerging strategies for supporting faster, more predictable recovery.
Dr. Kapp opened by highlighting a key challenge: although chronic wounds dominate public attention, nearly 30% of surgical wounds experience delayed healing, particularly among older adults and those with diabetes, vascular disease, or compromised immune responses . With more than 3–6 million Americans affected each year, the downstream burden on both clinical teams and patients is substantial.
Through a series of real-world cases, Dr. Kapp illustrated how Bonvadis® can support wound progression even when prior standard-of-care treatments fail to achieve momentum.
Case Highlights
1. Non-healing biopsy site (77-year-old female)
- Chronic non-epithelializing wound for 3 weeks despite Santyl + silver nitrate
- Bonvadis® once daily → full epithelialization in 3 weeks
2. MOHs surgical site with local infection (80-year-old male)
- Progressed through sequential management: debridement → Bonvadis® → CAMPs product
- Showed consistent weekly improvement, with strong tissue response by Week 4
3. Full-thickness skin graft
- Post-operative Bonvadis® used to maintain wound stability and support surface healing
Across these examples, Dr. Kapp emphasized three recurring principles:
- The wound bed must be stabilized early to avoid prolonged inflammation
- Adjuncts must integrate seamlessly with SOC (debridement, infection control, grafting)
- Ease of use matters—clinicians and patients need straightforward regimens that support daily healing
Throughout the presentation, attendees raised questions around patient selection, compatibility with NPWT, and integration into post-reconstruction pathways. Dr. Kapp reinforced that predictable healing often hinges on addressing inflammation and supporting tissue remodeling from the outset, areas where Bonvadis® has demonstrated meaningful clinical benefit.
His closing message underscored a shared objective across wound-care specialties: enabling patients to return to normal life sooner by reducing the friction and uncertainty of the healing journey.
